Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22246773 | 0.81 | MERTK (0.37) | RAB9AEPHX2EPHX1MEN1KMT2A | |
| SCHEMBL25120757 | 0.67 | HPGD (0.42) | HPGDSMN1; SMN2RAB9ATP53CCNE1 | |
| SCHEMBL23719136 | 0.66 | EPHX1 (0.49) | ATRHPGDSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3433977 | 0.63 | SMN1; SMN2 (0.65) | HPGDSMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL28798411 | 0.62 | ATM (0.68) | HPGDSMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL19703413 | 0.62 | HPGD (1.00) | HPGDMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1300190 | 0.62 | HPGD (1.00) | HPGDMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4051171 | 0.62 | RAB9A (0.69) | SMN1; SMN2RAB9ANPC1KDM4EMEN1 | |
| SCHEMBL420582 | 0.62 | RAB9A (0.69) | SMN1; SMN2RAB9ANPC1KDM4EMEN1 | |
| SCHEMBL15652085 | 0.62 | MAP4K4 (0.35) | KDM4ECDK2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | ATR 241/4885HPGD 3415/4885SMN1; SMN2 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.